Nine weeks versus 1 year adjuvant trastuzumab in patients with early breast cancer: an observational study by the Turkish Oncology Group (TOG)

Icli, Fikri; Altundag, Kadri; AKBULUT, HAKAN; PAYDAŞ, SEMRA; BAŞARAN, Gül; SAİP, Pınar; Dogu, Gamze; Erlap, YEŞİM; Uslu, Ruchan; Sevinc, Alper; Onur, Handan; Mandel, Nil; Sezgin, Canfeza; Altinbas, Mustafa; Guler, Nilufer; Isikdogan, Abdurrahman; Gokmen, Erhan; Uygun, Kazim; Ustuner, Zeki; Yaren, Arzu; Demirkan, Binnaz; Coskun, Ugur; Ata, Alper; Ozkan, Metin; Arican, Ali

doi:10.1007/s12282-013-0506-y

Nine weeks versus 1 year adjuvant trastuzumab in patients with early breast cancer: an observational study by the Turkish Oncology Group (TOG)

Atıf İçin Kopyala

Icli F., Altundag K., AKBULUT H., PAYDAŞ S., BAŞARAN G., SAİP P. M., ...Daha Fazla

BREAST CANCER, cilt.22, sa.5, ss.480-485, 2015 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 22 Sayı: 5
Basım Tarihi: 2015
Doi Numarası: 10.1007/s12282-013-0506-y
Dergi Adı: BREAST CANCER
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.480-485
Anahtar Kelimeler: Adjuvant treatment, Nine weeks trastuzumab, Cardiotoxicity, Early breast cancer, CHEMOTHERAPY, XENOGRAFTS, ANTIBODY, RECEPTOR, THERAPY
Acıbadem Mehmet Ali Aydınlar Üniversitesi Adresli: Evet

Özet

Background Optimal duration of adjuvant trastuzumab in early breast cancer is an unresolved issue. In this observational study, we compared the outcome of 9 weeks and 1 year adjuvant trastuzumab in early breast cancer patients in Turkey.